November 28, 2023 7:27am

A lot of fuss about degrading sessions that ultimately affects the cell and gene therapy sector

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed!

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what could happen or materialize

 

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

 

The pre-open Dow futures are DOWN -0.01% or (-4 points), the S&P is DOWN -0.08% or (-4 points) as the Nasdaq is DOWN -0.07% or (-10 points)

Stock futures are down incrementally on Tuesday

European markets fell,

Asia-Pacific markets were mixed on Tuesday.

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes collapsed as the major averages missed creating a four-week winning streak; while the Dow closed DOWN -56.68 points or -0.16%, the S&P closed DOWN -8.91 points or -0.20% while the Nasdaq closed DOWN -9.83 points or -0.07%.

Yesterday, a larger than expected drop in new home sales added to the subdued tone.

Monday’s modest retreat comes near the end of November’s strong trading month, which concludes with Thursday’s close.

Economic Data Docket: housing prices and consumer confidence

 

Monday, RegMed Investors (RMi) Closing Bell: “Cell and gene therapy sector slips” … https://www.regmedinvestors.com/articles/13220

RegMed Investors (RMi) - Q3/23 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Q4: November – 10 positive and 8 negative closes

·         October – 1 sick day, 9 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: looking for lost SHEAP …

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

I am passing on forecasting the daily indications; it’s just too jumbled and mixed signals, followed by a weak aftermarket as markets fluctuate after four (4) weeks floating to the upside and hope is not a good strategy…

 

The BOTTOM LINE:  I STILL believe some cell and gene therapy sector upsiders are … overbought.

I am STILL waiting for catalysts to justify recent upside appreciation other than algorithmic electronic trading!

  • I also DON’T believe totally in the THIS market -- it’s usually a signal to lighten the load of the sector’s upside movers.
  • Being that I have concerns over the resiliency of upside moves that usually end in downward sells as the risk/reward profile doesn’t always compel elevated and “dramatic” i.e., sudden equity pricing.
  • It might be prudent to harvest and cash in some chips following the past month’s dramatic rally.

 

Today’s relevancy from Monday’s session:

  • The small-cap Russell 2000 advanced 0.5% for the week, slightly below the 200-day moving average.
  • The 10-year Treasury yield rose 4 basis points to 4.48%, rebounding Friday from two-month lows.
  • Excessive bullishness or complacency could foreshadow some sort of pullback. So do other measures signaling the market is getting overbought. But a pullback doesn't have to happen right away and it wouldn't have to be sharp or last long.
  • Investors should be very cautious, holding to some positions and building cash if possible!

 

So, it's time to think ahead to December. It's usually an important month for the Nasdaq.

  • But, don’t FORGET portfolio tax selling and a bit of rebalancing
  • And then comes January and with worries that the U.S. economy will be slowing down, the potential for continued Middle East violence and, of course, the real prospect of bitterly contested elections across all of the United States. <The Street>

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.